NCT07909915Not yet recruitingPhase 4
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
To compare the efficacy of fixed-dose versus treat-to-target statin regimens in achieving the predefined LDL-C target at 12 weeks in patients with established ASCVD. To compare the frequency of adverse effects of statin therapy between patients receiving a fixed-dose regimen and those managed with a treat-to-target approach.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- First submitted
- 26 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Rehman Medical Institute - RMI
- Diseases
- Familial hypercholesterolaemia, Stroke
- NCT number
- NCT07909915
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 178
- From Nov 2026 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- i) have already achieved target LDL-C levels on a high-dose statin and tolerate it well, ii) have contraindications to statin therapy such as active liver disease or severe renal impairment (eGFR \< 30 mL/min/1.73m²), iii) have known hypersensitivity or a prior life-threatening reaction to any statin, iv) are pregnant or lactating, or v) are using other lipid-lowering agents like ezetimibe, PCSK9 inhibitors, fibrates, or bile acid sequestrants.
Who the study is looking for
- i) adults aged between 18 to 80 years requiring primary prevention or those with history of at least 1 episode of ASCVD, ii) who are either statin-naïve or already on statins but not at target LDL-C levels and are eligible for dose adjustment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rehman Medical Institute Coordinator of this site? Confirm its status | Peshawar | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.